Skip to content
Whale Atlas — Follow the signal.
Home
FULL RECORDS
Search insider filingsAll Congress filings
MORE TOOLS
WatchlistGold IntelligencePeopleCharts & technicalsCompany financialsOfficial newsMy saved workspace
YOUR RESEARCH
HomeSearch insider filingsAll Congress filings
More research tools
ExploreGold IntelligencePeopleInvestigate an ideaCharts & technicalsMore evidenceCompany financialsOfficial newsMy research & helpWatchlistMy saved workspaceLearn the basicsHow signals workData & coverage
RESOURCES
LearnMethodologyData sources
Built on public evidence.

Primary sources. Clear reasoning.
No black boxes.

Our approach
Public research workspacev1.0

Loading data…Scanning SEC filings…Checking Congress reports…Following the signal…

HomeSearchCongressWatchlist
© 2026 Whale AtlasFree public-filing research. Not financial advice. By using this site you agree to the Terms of Use.
FAQCompare trackersMethodologyData & correctionsTermsPrivacy
Back to Home
A

ALKS

Nasdaq

Alkermes plc.

Latest disclosureOctober 2, 2026
Insider score Why 0?
0/ 100
Qualifying buys · 30d
$0

0 purchases · 19 sales

Price by TradingViewDelayed quote from TradingView, for viewing only. It does not power Whale Atlas scores or alerts. If the quote does not load, open the TradingView link.

Insider transactions 90

Limited filing history
All90Buying0Selling19Other71
Filters

Last 30 daysNo qualifying insider buying. Sales: $83.46K by 1 insider.

90 trades · April 1, 2026 – October 2, 2026Incomplete history: this shows the filings imported so far, not every filing ever made. Dates are trade dates. Filters affect this table only.

Showing the first 6 of 90 trades on this page.

Sale disclosed

David Joseph Gaffin

EVP, CLO, Alkermes, Inc.

Ordinary Shares

Reported value
$83.46K
Reported price
$41.03 / share
Traded October 2, 2026Filed October 2, 2026SEC filing
Sale disclosed

David Joseph Gaffin

EVP, CLO, Alkermes, Inc.

Ordinary Shares

Reported value
$97.65K
Reported price
$48.01 / share
Traded September 3, 2026Filed September 3, 2026SEC filing
Exercise or conversion

Craig C. Hopkinson

EVP R&D, Chief Medical Officer

Ordinary Shares

Value context
$122.95K
Reported price
$24.59 / share
Traded September 1, 2026Filed September 1, 2026SEC filing
Sale disclosed

Craig C. Hopkinson

EVP R&D, Chief Medical Officer

Ordinary Shares

Reported value
$422.87K
Reported price
$46.986 / share
Traded September 1, 2026Filed September 1, 2026SEC filing
Exercise or conversion

Craig C. Hopkinson

EVP R&D, Chief Medical Officer

Employee Stock Option (Right to Buy)

Derivative security · not the ordinary share price.

Value context
Not a separate purchase
Exercise / conversion price
$24.59 exercise / conversion price
Understand this price

This row records an option exercise or conversion. The derivative transaction price is separate from the exercise price; it is not the stock's market price. Its row value is not shown as another stock purchase.

Traded September 1, 2026Filed September 1, 2026SEC filing
Sale disclosed

Christian Todd Nichols

SVP, Chief Commercial Officer

Ordinary Shares

Reported value
$339.97K
Reported price
$49.1851 / share
Traded August 17, 2026Filed August 17, 2026SEC filing
Sale disclosed

Christian Todd Nichols

SVP, Chief Commercial Officer

Ordinary Shares

Reported value
$32.97K
Reported price
$49.6526 / share
Traded August 17, 2026Filed August 17, 2026SEC filing
Award disclosed

Blair Curtis Jackson

President & CEO, Alkermes plc

Employee Stock Option (Right to Buy)

Derivative security · not the ordinary share price.

Value context
Non-cash award
Reported price
Award · no purchase price
Understand this price

The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.

Traded August 5, 2026Filed August 7, 2026SEC filing
Award disclosed

Blair Curtis Jackson

President & CEO, Alkermes plc

Employee Stock Option (Right to Buy)

Derivative security · not the ordinary share price.

Value context
Non-cash award
Reported price
Award · no purchase price
Understand this price

The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.

Traded August 5, 2026Filed August 7, 2026SEC filing
Exercise or conversion

nancy lynn MD snyderman

Director

Ordinary Shares

Value context
$1.31M
Reported price
$46.72 / share
Traded August 3, 2026Filed August 3, 2026SEC filing
Exercise or conversion

nancy lynn MD snyderman

Director

Ordinary Shares

Value context
$772K
Reported price
$46.72 / share
Traded August 3, 2026Filed August 3, 2026SEC filing
Sale disclosed

nancy lynn MD snyderman

Director

Ordinary Shares

Reported value
$2.24M
Reported price
$50.348 / share
Traded August 3, 2026Filed August 3, 2026SEC filing
Exercise or conversion

nancy lynn MD snyderman

Director

Non Qualified Stock Option (Right to Buy)

Derivative security · not the ordinary share price.

Value context
Not a separate purchase
Exercise / conversion price
$46.72 exercise / conversion price
Understand this price

This row records an option exercise or conversion. The derivative transaction price is separate from the exercise price; it is not the stock's market price. Its row value is not shown as another stock purchase.

Traded August 3, 2026Filed August 3, 2026SEC filing
Exercise or conversion

nancy lynn MD snyderman

Director

Non Qualified Stock Option (Right to Buy)

Derivative security · not the ordinary share price.

Value context
Not a separate purchase
Exercise / conversion price
$46.72 exercise / conversion price
Understand this price

This row records an option exercise or conversion. The derivative transaction price is separate from the exercise price; it is not the stock's market price. Its row value is not shown as another stock purchase.

Traded August 3, 2026Filed August 3, 2026SEC filing
Exercise or conversion

Craig C. Hopkinson

EVP R&D, Chief Medical Officer

Ordinary Shares

Value context
$2.01K
Reported price
$19.34 / share
Traded August 3, 2026Filed August 3, 2026SEC filing
Exercise or conversion

Craig C. Hopkinson

EVP R&D, Chief Medical Officer

Ordinary Shares

Value context
$120.39K
Reported price
$24.59 / share
Traded August 3, 2026Filed August 3, 2026SEC filing
Sale disclosed

Craig C. Hopkinson

EVP R&D, Chief Medical Officer

Ordinary Shares

Reported value
$437.22K
Reported price
$48.58 / share
Traded August 3, 2026Filed August 3, 2026SEC filing
Exercise or conversion

Craig C. Hopkinson

EVP R&D, Chief Medical Officer

Employee Stock Option (Right to Buy)

Derivative security · not the ordinary share price.

Value context
Not a separate purchase
Exercise / conversion price
$19.34 exercise / conversion price
Understand this price

This row records an option exercise or conversion. The derivative transaction price is separate from the exercise price; it is not the stock's market price. Its row value is not shown as another stock purchase.

Traded August 3, 2026Filed August 3, 2026SEC filing
Exercise or conversion

Craig C. Hopkinson

EVP R&D, Chief Medical Officer

Employee Stock Option (Right to Buy)

Derivative security · not the ordinary share price.

Value context
Not a separate purchase
Exercise / conversion price
$24.59 exercise / conversion price
Understand this price

This row records an option exercise or conversion. The derivative transaction price is separate from the exercise price; it is not the stock's market price. Its row value is not shown as another stock purchase.

Traded August 3, 2026Filed August 3, 2026SEC filing
Sale disclosed

David Joseph Gaffin

EVP, CLO, Alkermes, Inc.

Ordinary Shares

Reported value
$98.81K
Reported price
$48.58 / share
Traded August 3, 2026Filed August 3, 2026SEC filing
Sale disclosed

David Joseph Gaffin

EVP, CLO, Alkermes, Inc.

Ordinary Shares

Reported value
$109.9K
Reported price
$54.03 / share
Traded July 6, 2026Filed July 6, 2026SEC filing
Exercise or conversion

Craig C. Hopkinson

EVP R&D, Chief Medical Officer

Ordinary Shares

Value context
$96.7K
Reported price
$19.34 / share
Traded July 1, 2026Filed July 1, 2026SEC filing
Sale disclosed

Craig C. Hopkinson

EVP R&D, Chief Medical Officer

Ordinary Shares

Reported value
$427.13K
Reported price
$51.4613 / share
Traded July 1, 2026Filed July 1, 2026SEC filing
Sale disclosed

Craig C. Hopkinson

EVP R&D, Chief Medical Officer

Ordinary Shares

Reported value
$36.49K
Reported price
$52.1314 / share
Traded July 1, 2026Filed July 1, 2026SEC filing
Exercise or conversion

Craig C. Hopkinson

EVP R&D, Chief Medical Officer

Employee Stock Option (Right to Buy)

Derivative security · not the ordinary share price.

Value context
Not a separate purchase
Exercise / conversion price
$19.34 exercise / conversion price
Understand this price

This row records an option exercise or conversion. The derivative transaction price is separate from the exercise price; it is not the stock's market price. Its row value is not shown as another stock purchase.

Traded July 1, 2026Filed July 1, 2026SEC filing
Sale disclosed

Christopher I. Wright

Director

Ordinary Shares

Reported value
$90.2K
Reported price
$45.10 / share
Traded June 12, 2026Filed June 12, 2026SEC filing
Sale disclosed

David Joseph Gaffin

EVP, CLO, Alkermes, Inc.

Ordinary Shares

Reported value
$87.56K
Reported price
$43.05 / share
Traded June 4, 2026Filed June 4, 2026SEC filing
Exercise or conversion

Craig C. Hopkinson

EVP R&D, Chief Medical Officer

Ordinary Shares

Value context
$96.7K
Reported price
$19.34 / share
Traded June 1, 2026Filed June 1, 2026SEC filing
Sale disclosed

Craig C. Hopkinson

EVP R&D, Chief Medical Officer

Ordinary Shares

Reported value
$375.04K
Reported price
$41.6715 / share
Traded June 1, 2026Filed June 1, 2026SEC filing
Exercise or conversion

Craig C. Hopkinson

EVP R&D, Chief Medical Officer

Employee Stock Option (Right to Buy)

Derivative security · not the ordinary share price.

Value context
Not a separate purchase
Exercise / conversion price
$19.34 exercise / conversion price
Understand this price

This row records an option exercise or conversion. The derivative transaction price is separate from the exercise price; it is not the stock's market price. Its row value is not shown as another stock purchase.

Traded June 1, 2026Filed June 1, 2026SEC filing
Exercise or conversion

Samuel Joseph Parisi

VP, Finance (Interim PAO)

Ordinary Shares

Value context
$67.94K
Reported price
$20.03 / share
Traded May 29, 2026Filed May 29, 2026SEC filing
Exercise or conversion

Samuel Joseph Parisi

VP, Finance (Interim PAO)

Ordinary Shares

Value context
$248.04K
Reported price
$19.34 / share
Traded May 29, 2026Filed May 29, 2026SEC filing
Sale disclosed

Samuel Joseph Parisi

VP, Finance (Interim PAO)

Ordinary Shares

Reported value
$687.01K
Reported price
$42.3634 / share
Traded May 29, 2026Filed May 29, 2026SEC filing
Exercise or conversion

Samuel Joseph Parisi

VP, Finance (Interim PAO)

Employee Stock Option (Right to Buy)

Derivative security · not the ordinary share price.

Value context
Not a separate purchase
Exercise / conversion price
$20.03 exercise / conversion price
Understand this price

This row records an option exercise or conversion. The derivative transaction price is separate from the exercise price; it is not the stock's market price. Its row value is not shown as another stock purchase.

Traded May 29, 2026Filed May 29, 2026SEC filing
Exercise or conversion

Samuel Joseph Parisi

VP, Finance (Interim PAO)

Employee Stock Option (Right to Buy)

Derivative security · not the ordinary share price.

Value context
Not a separate purchase
Exercise / conversion price
$19.34 exercise / conversion price
Understand this price

This row records an option exercise or conversion. The derivative transaction price is separate from the exercise price; it is not the stock's market price. Its row value is not shown as another stock purchase.

Traded May 29, 2026Filed May 29, 2026SEC filing
Exercise or conversion

Christopher I. Wright

Director

Ordinary Shares

Value context
Unavailable
Reported price
Price not reported
Traded May 21, 2026Filed May 22, 2026SEC filing
Tax or exercise withholding

Christopher I. Wright

Director

Ordinary Shares

Value context
$54.5K
Reported price
$36.95 / share
Traded May 21, 2026Filed May 22, 2026SEC filing
Award disclosed

Christopher I. Wright

Director

Non Qualified Stock Option (Right to Buy)

Derivative security · not the ordinary share price.

Value context
Non-cash award
Reported price
Award · no purchase price
Understand this price

The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.

Traded May 20, 2026Filed May 22, 2026SEC filing
Award disclosed

Christopher I. Wright

Director

Restricted Stock Unit Award

Derivative security · not the ordinary share price.

Value context
Non-cash award
Reported price
Award · no purchase price
Understand this price

The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.

Traded May 20, 2026Filed May 22, 2026SEC filing
Exercise or conversion

Christopher I. Wright

Director

Restricted Stock Unit Award

Derivative security · not the ordinary share price.

Value context
Not a separate purchase
Exercise / conversion price
Exercise / conversion price not reported
Understand this price

This row records an option exercise or conversion. The derivative transaction price is separate from the exercise price; it is not the stock's market price. Its row value is not shown as another stock purchase.

Traded May 21, 2026Filed May 22, 2026SEC filing
Exercise or conversion

Frank Anders Wilson

Director

Ordinary Shares

Value context
Unavailable
Reported price
Price not reported
Traded May 21, 2026Filed May 22, 2026SEC filing
Tax or exercise withholding

Frank Anders Wilson

Director

Ordinary Shares

Value context
$54.5K
Reported price
$36.95 / share
Traded May 21, 2026Filed May 22, 2026SEC filing
Award disclosed

Frank Anders Wilson

Director

Non Qualified Stock Option (Right to Buy)

Derivative security · not the ordinary share price.

Value context
Non-cash award
Reported price
Award · no purchase price
Understand this price

The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.

Traded May 20, 2026Filed May 22, 2026SEC filing
Award disclosed

Frank Anders Wilson

Director

Restricted Stock Unit Award

Derivative security · not the ordinary share price.

Value context
Non-cash award
Reported price
Award · no purchase price
Understand this price

The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.

Traded May 20, 2026Filed May 22, 2026SEC filing
Exercise or conversion

Frank Anders Wilson

Director

Restricted Stock Unit Award

Derivative security · not the ordinary share price.

Value context
Not a separate purchase
Exercise / conversion price
Exercise / conversion price not reported
Understand this price

This row records an option exercise or conversion. The derivative transaction price is separate from the exercise price; it is not the stock's market price. Its row value is not shown as another stock purchase.

Traded May 21, 2026Filed May 22, 2026SEC filing
Exercise or conversion

nancy lynn MD snyderman

Director

Ordinary Shares

Value context
Unavailable
Reported price
Price not reported
Traded May 21, 2026Filed May 22, 2026SEC filing
Tax or exercise withholding

nancy lynn MD snyderman

Director

Ordinary Shares

Value context
$54.5K
Reported price
$36.95 / share
Traded May 21, 2026Filed May 22, 2026SEC filing
Award disclosed

nancy lynn MD snyderman

Director

Non Qualified Stock Option (Right to Buy)

Derivative security · not the ordinary share price.

Value context
Non-cash award
Reported price
Award · no purchase price
Understand this price

The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.

Traded May 20, 2026Filed May 22, 2026SEC filing
Award disclosed

nancy lynn MD snyderman

Director

Restricted Stock Unit Award

Derivative security · not the ordinary share price.

Value context
Non-cash award
Reported price
Award · no purchase price
Understand this price

The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.

Traded May 20, 2026Filed May 22, 2026SEC filing
Exercise or conversion

nancy lynn MD snyderman

Director

Restricted Stock Unit Award

Derivative security · not the ordinary share price.

Value context
Not a separate purchase
Exercise / conversion price
Exercise / conversion price not reported
Understand this price

This row records an option exercise or conversion. The derivative transaction price is separate from the exercise price; it is not the stock's market price. Its row value is not shown as another stock purchase.

Traded May 21, 2026Filed May 22, 2026SEC filing
Exercise or conversion

Brian P. Mckeon

Director

Ordinary Shares

Value context
Unavailable
Reported price
Price not reported
Traded May 21, 2026Filed May 22, 2026SEC filing
Tax or exercise withholding

Brian P. Mckeon

Director

Ordinary Shares

Value context
$54.5K
Reported price
$36.95 / share
Traded May 21, 2026Filed May 22, 2026SEC filing
Award disclosed

Brian P. Mckeon

Director

Non Qualified Stock Option (Right to Buy)

Derivative security · not the ordinary share price.

Value context
Non-cash award
Reported price
Award · no purchase price
Understand this price

The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.

Traded May 20, 2026Filed May 22, 2026SEC filing
Award disclosed

Brian P. Mckeon

Director

Restricted Stock Unit Award

Derivative security · not the ordinary share price.

Value context
Non-cash award
Reported price
Award · no purchase price
Understand this price

The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.

Traded May 20, 2026Filed May 22, 2026SEC filing
Exercise or conversion

Brian P. Mckeon

Director

Restricted Stock Unit Award

Derivative security · not the ordinary share price.

Value context
Not a separate purchase
Exercise / conversion price
Exercise / conversion price not reported
Understand this price

This row records an option exercise or conversion. The derivative transaction price is separate from the exercise price; it is not the stock's market price. Its row value is not shown as another stock purchase.

Traded May 21, 2026Filed May 22, 2026SEC filing
Exercise or conversion

Nancy Lurker

Director

Ordinary Shares

Value context
Unavailable
Reported price
Price not reported
Traded May 21, 2026Filed May 22, 2026SEC filing
Tax or exercise withholding

Nancy Lurker

Director

Ordinary Shares

Value context
$54.5K
Reported price
$36.95 / share
Traded May 21, 2026Filed May 22, 2026SEC filing
Award disclosed

Nancy Lurker

Director

Non Qualified Stock Option (Right to Buy)

Derivative security · not the ordinary share price.

Value context
Non-cash award
Reported price
Award · no purchase price
Understand this price

The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.

Traded May 20, 2026Filed May 22, 2026SEC filing
Award disclosed

Nancy Lurker

Director

Restricted Stock Unit Award

Derivative security · not the ordinary share price.

Value context
Non-cash award
Reported price
Award · no purchase price
Understand this price

The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.

Traded May 20, 2026Filed May 22, 2026SEC filing
Exercise or conversion

Nancy Lurker

Director

Restricted Stock Unit Award

Derivative security · not the ordinary share price.

Value context
Not a separate purchase
Exercise / conversion price
Exercise / conversion price not reported
Understand this price

This row records an option exercise or conversion. The derivative transaction price is separate from the exercise price; it is not the stock's market price. Its row value is not shown as another stock purchase.

Traded May 21, 2026Filed May 22, 2026SEC filing
Exercise or conversion

Cato T. Laurencin

Director

Ordinary Shares

Value context
Unavailable
Reported price
Price not reported
Traded May 21, 2026Filed May 22, 2026SEC filing
Tax or exercise withholding

Cato T. Laurencin

Director

Ordinary Shares

Value context
$54.5K
Reported price
$36.95 / share
Traded May 21, 2026Filed May 22, 2026SEC filing
Award disclosed

Cato T. Laurencin

Director

Non Qualified Stock Option (Right to Buy)

Derivative security · not the ordinary share price.

Value context
Non-cash award
Reported price
Award · no purchase price
Understand this price

The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.

Traded May 20, 2026Filed May 22, 2026SEC filing
Award disclosed

Cato T. Laurencin

Director

Restricted Stock Unit Award

Derivative security · not the ordinary share price.

Value context
Non-cash award
Reported price
Award · no purchase price
Understand this price

The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.

Traded May 20, 2026Filed May 22, 2026SEC filing
Exercise or conversion

Cato T. Laurencin

Director

Restricted Stock Unit Award

Derivative security · not the ordinary share price.

Value context
Not a separate purchase
Exercise / conversion price
Exercise / conversion price not reported
Understand this price

This row records an option exercise or conversion. The derivative transaction price is separate from the exercise price; it is not the stock's market price. Its row value is not shown as another stock purchase.

Traded May 21, 2026Filed May 22, 2026SEC filing
Award disclosedAmended filing

Richard Gaynor

Director

Amended

Related filings are retained as evidence. This economic transaction is counted once.

This amendment supersedes the related original transaction.

Original SEC filing ↗Amended SEC filing ↗

Non Qualified Stock Option (Right to Buy)

Derivative security · not the ordinary share price.

Value context
Non-cash award
Reported price
Award · no purchase price
Understand this price

The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.

Traded May 20, 2026Filed May 22, 2026SEC filing
Award disclosedAmended filing

Richard Gaynor

Director

Amended

Related filings are retained as evidence. This economic transaction is counted once.

This amendment supersedes the related original transaction.

Original SEC filing ↗Amended SEC filing ↗

Restricted Stock Unit Award

Derivative security · not the ordinary share price.

Value context
Non-cash award
Reported price
Award · no purchase price
Understand this price

The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.

Traded May 20, 2026Filed May 22, 2026SEC filing
Award disclosedAmended filing

Shane Cooke

Director

Amended

Related filings are retained as evidence. This economic transaction is counted once.

This amendment supersedes the related original transaction.

Original SEC filing ↗Amended SEC filing ↗

Non Qualified Stock Option (Right to Buy)

Derivative security · not the ordinary share price.

Value context
Non-cash award
Reported price
Award · no purchase price
Understand this price

The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.

Traded May 20, 2026Filed May 22, 2026SEC filing
Award disclosedAmended filing

Shane Cooke

Director

Amended

Related filings are retained as evidence. This economic transaction is counted once.

This amendment supersedes the related original transaction.

Original SEC filing ↗Amended SEC filing ↗

Restricted Stock Unit Award

Derivative security · not the ordinary share price.

Value context
Non-cash award
Reported price
Award · no purchase price
Understand this price

The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.

Traded May 20, 2026Filed May 22, 2026SEC filing
Exercise or conversion

Richard Gaynor

Director

Ordinary Shares

Value context
Unavailable
Reported price
Price not reported
Traded May 21, 2026Filed May 22, 2026SEC filing
Tax or exercise withholding

Richard Gaynor

Director

Ordinary Shares

Value context
$54.5K
Reported price
$36.95 / share
Traded May 21, 2026Filed May 22, 2026SEC filing
Award disclosed

Richard Gaynor

Director

Superseded by later filing

Related filings are retained as evidence. This economic transaction is counted once.

This original record remains available as evidence. The later filing replaces it in totals and buying signals.

Superseding SEC filing ↗Original transaction filing ↗

Non Qualified Stock Option (Right to Buy)

Derivative security · not the ordinary share price.

Value context
Non-cash award
Reported price
Award · no purchase price
Understand this price

The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.

Traded May 20, 2026Filed May 22, 2026SEC filing
Award disclosed

Richard Gaynor

Director

Superseded by later filing

Related filings are retained as evidence. This economic transaction is counted once.

This original record remains available as evidence. The later filing replaces it in totals and buying signals.

Superseding SEC filing ↗Original transaction filing ↗

Restricted Stock Unit Award

Derivative security · not the ordinary share price.

Value context
Non-cash award
Reported price
Award · no purchase price
Understand this price

The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.

Traded May 20, 2026Filed May 22, 2026SEC filing
Exercise or conversion

Richard Gaynor

Director

Restricted Stock Unit Award

Derivative security · not the ordinary share price.

Value context
Not a separate purchase
Exercise / conversion price
Exercise / conversion price not reported
Understand this price

This row records an option exercise or conversion. The derivative transaction price is separate from the exercise price; it is not the stock's market price. Its row value is not shown as another stock purchase.

Traded May 21, 2026Filed May 22, 2026SEC filing
Exercise or conversion

Shane Cooke

Director

Ordinary Shares

Value context
Unavailable
Reported price
Price not reported
Traded May 21, 2026Filed May 22, 2026SEC filing
Tax or exercise withholding

Shane Cooke

Director

Ordinary Shares

Value context
$118.5K
Reported price
$36.95 / share
Traded May 21, 2026Filed May 22, 2026SEC filing
Award disclosed

Shane Cooke

Director

Superseded by later filing

Related filings are retained as evidence. This economic transaction is counted once.

This original record remains available as evidence. The later filing replaces it in totals and buying signals.

Superseding SEC filing ↗Original transaction filing ↗

Non Qualified Stock Option (Right to Buy)

Derivative security · not the ordinary share price.

Value context
Non-cash award
Reported price
Award · no purchase price
Understand this price

The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.

Traded May 20, 2026Filed May 22, 2026SEC filing
Award disclosed

Shane Cooke

Director

Superseded by later filing

Related filings are retained as evidence. This economic transaction is counted once.

This original record remains available as evidence. The later filing replaces it in totals and buying signals.

Superseding SEC filing ↗Original transaction filing ↗

Restricted Stock Unit Award

Derivative security · not the ordinary share price.

Value context
Non-cash award
Reported price
Award · no purchase price
Understand this price

The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.

Traded May 20, 2026Filed May 22, 2026SEC filing
Exercise or conversion

Shane Cooke

Director

Restricted Stock Unit Award

Derivative security · not the ordinary share price.

Value context
Not a separate purchase
Exercise / conversion price
Exercise / conversion price not reported
Understand this price

This row records an option exercise or conversion. The derivative transaction price is separate from the exercise price; it is not the stock's market price. Its row value is not shown as another stock purchase.

Traded May 21, 2026Filed May 22, 2026SEC filing
Sale disclosed

David Joseph Gaffin

EVP, CLO, Alkermes, Inc.

Ordinary Shares

Reported value
$67.53K
Reported price
$33.20 / share
Traded May 4, 2026Filed May 4, 2026SEC filing
Exercise or conversion

Craig C. Hopkinson

EVP R&D, Chief Medical Officer

Ordinary Shares

Value context
$96.7K
Reported price
$19.34 / share
Traded May 1, 2026Filed May 1, 2026SEC filing
Sale disclosed

Craig C. Hopkinson

EVP R&D, Chief Medical Officer

Ordinary Shares

Reported value
$300.56K
Reported price
$33.3955 / share
Traded May 1, 2026Filed May 1, 2026SEC filing
Exercise or conversion

Craig C. Hopkinson

EVP R&D, Chief Medical Officer

Employee Stock Option (Right to Buy)

Derivative security · not the ordinary share price.

Value context
Not a separate purchase
Exercise / conversion price
$19.34 exercise / conversion price
Understand this price

This row records an option exercise or conversion. The derivative transaction price is separate from the exercise price; it is not the stock's market price. Its row value is not shown as another stock purchase.

Traded May 1, 2026Filed May 1, 2026SEC filing
Exercise or conversion

Nancy Lurker

Director

Ordinary Shares

Value context
Unavailable
Reported price
Price not reported
Traded April 11, 2026Filed April 13, 2026SEC filing
Tax or exercise withholding

Nancy Lurker

Director

Ordinary Shares

Value context
$30.06K
Reported price
$33.36 / share
Traded April 11, 2026Filed April 13, 2026SEC filing
Exercise or conversion

Nancy Lurker

Director

Restricted Stock Unit Award

Derivative security · not the ordinary share price.

Value context
Not a separate purchase
Exercise / conversion price
Exercise / conversion price not reported
Understand this price

This row records an option exercise or conversion. The derivative transaction price is separate from the exercise price; it is not the stock's market price. Its row value is not shown as another stock purchase.

Traded April 11, 2026Filed April 13, 2026SEC filing
Sale disclosed

David Joseph Gaffin

EVP, CLO, Alkermes, Inc.

Ordinary Shares

Reported value
$70.32K
Reported price
$34.57 / share
Traded April 6, 2026Filed April 6, 2026SEC filing
Exercise or conversion

Craig C. Hopkinson

EVP R&D, Chief Medical Officer

Ordinary Shares

Value context
$96.7K
Reported price
$19.34 / share
Traded April 1, 2026Filed April 1, 2026SEC filing
Sale disclosed

Craig C. Hopkinson

EVP R&D, Chief Medical Officer

Ordinary Shares

Reported value
$319.6K
Reported price
$35.5116 / share
Traded April 1, 2026Filed April 1, 2026SEC filing
Exercise or conversion

Craig C. Hopkinson

EVP R&D, Chief Medical Officer

Employee Stock Option (Right to Buy)

Derivative security · not the ordinary share price.

Value context
Not a separate purchase
Exercise / conversion price
$19.34 exercise / conversion price
Understand this price

This row records an option exercise or conversion. The derivative transaction price is separate from the exercise price; it is not the stock's market price. Its row value is not shown as another stock purchase.

Traded April 1, 2026Filed April 1, 2026SEC filing
Reporting insiderSecurity / transactionAmount / priceValueTraded / disclosedSource
EVP, CLO, Alkermes, Inc.Ordinary SharesSale10b5-12,034$41.03 / share$83.46KOct 2Filed Oct 2 · 0d laterSEC filing
EVP, CLO, Alkermes, Inc.Ordinary SharesSale10b5-12,034$48.01 / share$97.65KSep 3Filed Sep 3 · 0d laterSEC filing
EVP R&D, Chief Medical OfficerOrdinary SharesOption exercise or conversion10b5-15,000$24.59 / share$122.95KSep 1Filed Sep 1 · 0d laterSEC filing
EVP R&D, Chief Medical OfficerOrdinary SharesSale10b5-19,000$46.99 / share$422.87KSep 1Filed Sep 1 · 0d laterSEC filing
EVP R&D, Chief Medical OfficerEmployee Stock Option (Right to Buy)Option exercise or conversion10b5-1Derivative units5,000$24.59 exercise / conversion priceNot a separate purchaseSep 1Filed Sep 1 · 0d laterSEC filing
SVP, Chief Commercial OfficerOrdinary SharesSale10b5-12 trades7,576avg $49.23 / share$372.94KAug 17Filed Aug 17 · 0d later
2 filings
  • 6,912 @ $49.19 · $339.97KSEC filing
  • 664 @ $49.65 · $32.97KSEC filing
President & CEO, Alkermes plcEmployee Stock Option (Right to Buy)Grant or awardDerivative units93,229Award · no purchase priceNon-cash awardAug 5Filed Aug 7 · 2d laterSEC filing
President & CEO, Alkermes plcEmployee Stock Option (Right to Buy)Grant or awardDerivative units124,305Award · no purchase priceNon-cash awardAug 5Filed Aug 7 · 2d laterSEC filing
DirectorOrdinary SharesOption exercise or conversion27,948$46.72 / share$1.31MAug 3Filed Aug 3 · 0d laterSEC filing
DirectorOrdinary SharesOption exercise or conversion16,524$46.72 / share$772KAug 3Filed Aug 3 · 0d laterSEC filing
DirectorOrdinary SharesSale44,472$50.35 / share$2.24MAug 3Filed Aug 3 · 0d laterSEC filing
DirectorNon Qualified Stock Option (Right to Buy)Option exercise or conversionDerivative units27,948$46.72 exercise / conversion priceNot a separate purchaseAug 3Filed Aug 3 · 0d laterSEC filing
DirectorNon Qualified Stock Option (Right to Buy)Option exercise or conversionDerivative units16,524$46.72 exercise / conversion priceNot a separate purchaseAug 3Filed Aug 3 · 0d laterSEC filing
EVP R&D, Chief Medical OfficerOrdinary SharesOption exercise or conversion10b5-1104$19.34 / share$2.01KAug 3Filed Aug 3 · 0d laterSEC filing
EVP R&D, Chief Medical OfficerOrdinary SharesOption exercise or conversion10b5-14,896$24.59 / share$120.39KAug 3Filed Aug 3 · 0d laterSEC filing
EVP R&D, Chief Medical OfficerOrdinary SharesSale10b5-19,000$48.58 / share$437.22KAug 3Filed Aug 3 · 0d laterSEC filing
EVP R&D, Chief Medical OfficerEmployee Stock Option (Right to Buy)Option exercise or conversion10b5-1Derivative units104$19.34 exercise / conversion priceNot a separate purchaseAug 3Filed Aug 3 · 0d laterSEC filing
EVP R&D, Chief Medical OfficerEmployee Stock Option (Right to Buy)Option exercise or conversion10b5-1Derivative units4,896$24.59 exercise / conversion priceNot a separate purchaseAug 3Filed Aug 3 · 0d laterSEC filing
EVP, CLO, Alkermes, Inc.Ordinary SharesSale10b5-12,034$48.58 / share$98.81KAug 3Filed Aug 3 · 0d laterSEC filing
EVP, CLO, Alkermes, Inc.Ordinary SharesSale10b5-12,034$54.03 / share$109.9KJul 6Filed Jul 6 · 0d laterSEC filing
EVP R&D, Chief Medical OfficerOrdinary SharesOption exercise or conversion10b5-15,000$19.34 / share$96.7KJul 1Filed Jul 1 · 0d laterSEC filing
EVP R&D, Chief Medical OfficerOrdinary SharesSale10b5-12 trades9,000avg $51.51 / share$463.62KJul 1Filed Jul 1 · 0d later
2 filings
  • 8,300 @ $51.46 · $427.13KSEC filing
  • 700 @ $52.13 · $36.49KSEC filing
EVP R&D, Chief Medical OfficerEmployee Stock Option (Right to Buy)Option exercise or conversion10b5-1Derivative units5,000$19.34 exercise / conversion priceNot a separate purchaseJul 1Filed Jul 1 · 0d laterSEC filing
DirectorOrdinary SharesSale10b5-12,000$45.10 / share$90.2KJun 12Filed Jun 12 · 0d laterSEC filing
EVP, CLO, Alkermes, Inc.Ordinary SharesSale10b5-12,034$43.05 / share$87.56KJun 4Filed Jun 4 · 0d laterSEC filing
EVP R&D, Chief Medical OfficerOrdinary SharesOption exercise or conversion10b5-15,000$19.34 / share$96.7KJun 1Filed Jun 1 · 0d laterSEC filing
EVP R&D, Chief Medical OfficerOrdinary SharesSale10b5-19,000$41.67 / share$375.04KJun 1Filed Jun 1 · 0d laterSEC filing
EVP R&D, Chief Medical OfficerEmployee Stock Option (Right to Buy)Option exercise or conversion10b5-1Derivative units5,000$19.34 exercise / conversion priceNot a separate purchaseJun 1Filed Jun 1 · 0d laterSEC filing
VP, Finance (Interim PAO)Ordinary SharesOption exercise or conversion3,392$20.03 / share$67.94KMay 29Filed May 29 · 0d laterSEC filing
VP, Finance (Interim PAO)Ordinary SharesOption exercise or conversion12,825$19.34 / share$248.04KMay 29Filed May 29 · 0d laterSEC filing
VP, Finance (Interim PAO)Ordinary SharesSale16,217$42.36 / share$687.01KMay 29Filed May 29 · 0d laterSEC filing
VP, Finance (Interim PAO)Employee Stock Option (Right to Buy)Option exercise or conversionDerivative units3,392$20.03 exercise / conversion priceNot a separate purchaseMay 29Filed May 29 · 0d laterSEC filing
VP, Finance (Interim PAO)Employee Stock Option (Right to Buy)Option exercise or conversionDerivative units12,825$19.34 exercise / conversion priceNot a separate purchaseMay 29Filed May 29 · 0d laterSEC filing
DirectorOrdinary SharesOption exercise or conversion6,142Price not reportedUnavailableMay 21Filed May 22 · 1d laterSEC filing
DirectorOrdinary SharesExercise-price or tax withholding1,475$36.95 / share$54.5KMay 21Filed May 22 · 1d laterSEC filing
DirectorNon Qualified Stock Option (Right to Buy)Grant or awardDerivative units11,538Award · no purchase priceNon-cash awardMay 20Filed May 22 · 2d laterSEC filing
DirectorRestricted Stock Unit AwardGrant or awardDerivative units5,409Award · no purchase priceNon-cash awardMay 20Filed May 22 · 2d laterSEC filing
DirectorRestricted Stock Unit AwardOption exercise or conversionDerivative units6,142Exercise / conversion price not reportedNot a separate purchaseMay 21Filed May 22 · 1d laterSEC filing
DirectorOrdinary SharesOption exercise or conversion6,142Price not reportedUnavailableMay 21Filed May 22 · 1d laterSEC filing
DirectorOrdinary SharesExercise-price or tax withholding1,475$36.95 / share$54.5KMay 21Filed May 22 · 1d laterSEC filing
DirectorNon Qualified Stock Option (Right to Buy)Grant or awardDerivative units11,538Award · no purchase priceNon-cash awardMay 20Filed May 22 · 2d laterSEC filing
DirectorRestricted Stock Unit AwardGrant or awardDerivative units5,409Award · no purchase priceNon-cash awardMay 20Filed May 22 · 2d laterSEC filing
DirectorRestricted Stock Unit AwardOption exercise or conversionDerivative units6,142Exercise / conversion price not reportedNot a separate purchaseMay 21Filed May 22 · 1d laterSEC filing
DirectorOrdinary SharesOption exercise or conversion6,142Price not reportedUnavailableMay 21Filed May 22 · 1d laterSEC filing
DirectorOrdinary SharesExercise-price or tax withholding1,475$36.95 / share$54.5KMay 21Filed May 22 · 1d laterSEC filing
DirectorNon Qualified Stock Option (Right to Buy)Grant or awardDerivative units11,538Award · no purchase priceNon-cash awardMay 20Filed May 22 · 2d laterSEC filing
DirectorRestricted Stock Unit AwardGrant or awardDerivative units5,409Award · no purchase priceNon-cash awardMay 20Filed May 22 · 2d laterSEC filing
DirectorRestricted Stock Unit AwardOption exercise or conversionDerivative units6,142Exercise / conversion price not reportedNot a separate purchaseMay 21Filed May 22 · 1d laterSEC filing
DirectorOrdinary SharesOption exercise or conversion6,142Price not reportedUnavailableMay 21Filed May 22 · 1d laterSEC filing
DirectorOrdinary SharesExercise-price or tax withholding1,475$36.95 / share$54.5KMay 21Filed May 22 · 1d laterSEC filing
DirectorNon Qualified Stock Option (Right to Buy)Grant or awardDerivative units11,538Award · no purchase priceNon-cash awardMay 20Filed May 22 · 2d laterSEC filing
DirectorRestricted Stock Unit AwardGrant or awardDerivative units5,409Award · no purchase priceNon-cash awardMay 20Filed May 22 · 2d laterSEC filing
DirectorRestricted Stock Unit AwardOption exercise or conversionDerivative units6,142Exercise / conversion price not reportedNot a separate purchaseMay 21Filed May 22 · 1d laterSEC filing
DirectorOrdinary SharesOption exercise or conversion6,142Price not reportedUnavailableMay 21Filed May 22 · 1d laterSEC filing
DirectorOrdinary SharesExercise-price or tax withholding1,475$36.95 / share$54.5KMay 21Filed May 22 · 1d laterSEC filing
DirectorNon Qualified Stock Option (Right to Buy)Grant or awardDerivative units11,538Award · no purchase priceNon-cash awardMay 20Filed May 22 · 2d laterSEC filing
DirectorRestricted Stock Unit AwardGrant or awardDerivative units5,409Award · no purchase priceNon-cash awardMay 20Filed May 22 · 2d laterSEC filing
DirectorRestricted Stock Unit AwardOption exercise or conversionDerivative units6,142Exercise / conversion price not reportedNot a separate purchaseMay 21Filed May 22 · 1d laterSEC filing
DirectorOrdinary SharesOption exercise or conversion6,142Price not reportedUnavailableMay 21Filed May 22 · 1d laterSEC filing
DirectorOrdinary SharesExercise-price or tax withholding1,475$36.95 / share$54.5KMay 21Filed May 22 · 1d laterSEC filing
DirectorNon Qualified Stock Option (Right to Buy)Grant or awardDerivative units11,538Award · no purchase priceNon-cash awardMay 20Filed May 22 · 2d laterSEC filing
DirectorRestricted Stock Unit AwardGrant or awardDerivative units5,409Award · no purchase priceNon-cash awardMay 20Filed May 22 · 2d laterSEC filing
DirectorRestricted Stock Unit AwardOption exercise or conversionDerivative units6,142Exercise / conversion price not reportedNot a separate purchaseMay 21Filed May 22 · 1d laterSEC filing
Director
Amended

Related filings are retained as evidence. This economic transaction is counted once.

This amendment supersedes the related original transaction.

Original SEC filing ↗Amended SEC filing ↗
Non Qualified Stock Option (Right to Buy)Grant or awardDerivative units11,538Award · no purchase priceNon-cash awardMay 20Filed May 22 · 2d laterSEC filing
Director
Amended

Related filings are retained as evidence. This economic transaction is counted once.

This amendment supersedes the related original transaction.

Original SEC filing ↗Amended SEC filing ↗
Restricted Stock Unit AwardGrant or awardDerivative units5,409Award · no purchase priceNon-cash awardMay 20Filed May 22 · 2d laterSEC filing
Director
Amended

Related filings are retained as evidence. This economic transaction is counted once.

This amendment supersedes the related original transaction.

Original SEC filing ↗Amended SEC filing ↗
Non Qualified Stock Option (Right to Buy)Grant or awardDerivative units11,538Award · no purchase priceNon-cash awardMay 20Filed May 22 · 2d laterSEC filing
Director
Amended

Related filings are retained as evidence. This economic transaction is counted once.

This amendment supersedes the related original transaction.

Original SEC filing ↗Amended SEC filing ↗
Restricted Stock Unit AwardGrant or awardDerivative units5,409Award · no purchase priceNon-cash awardMay 20Filed May 22 · 2d laterSEC filing
DirectorOrdinary SharesOption exercise or conversion6,142Price not reportedUnavailableMay 21Filed May 22 · 1d laterSEC filing
DirectorOrdinary SharesExercise-price or tax withholding1,475$36.95 / share$54.5KMay 21Filed May 22 · 1d laterSEC filing
Director
Superseded by later filing

Related filings are retained as evidence. This economic transaction is counted once.

This original record remains available as evidence. The later filing replaces it in totals and buying signals.

Superseding SEC filing ↗Original transaction filing ↗
Non Qualified Stock Option (Right to Buy)Grant or awardDerivative units11,538Award · no purchase priceNon-cash awardMay 20Filed May 22 · 2d laterSEC filing
Director
Superseded by later filing

Related filings are retained as evidence. This economic transaction is counted once.

This original record remains available as evidence. The later filing replaces it in totals and buying signals.

Superseding SEC filing ↗Original transaction filing ↗
Restricted Stock Unit AwardGrant or awardDerivative units5,409Award · no purchase priceNon-cash awardMay 20Filed May 22 · 2d laterSEC filing
DirectorRestricted Stock Unit AwardOption exercise or conversionDerivative units6,142Exercise / conversion price not reportedNot a separate purchaseMay 21Filed May 22 · 1d laterSEC filing
DirectorOrdinary SharesOption exercise or conversion6,142Price not reportedUnavailableMay 21Filed May 22 · 1d laterSEC filing
DirectorOrdinary SharesExercise-price or tax withholding3,207$36.95 / share$118.5KMay 21Filed May 22 · 1d laterSEC filing
Director
Superseded by later filing

Related filings are retained as evidence. This economic transaction is counted once.

This original record remains available as evidence. The later filing replaces it in totals and buying signals.

Superseding SEC filing ↗Original transaction filing ↗
Non Qualified Stock Option (Right to Buy)Grant or awardDerivative units11,538Award · no purchase priceNon-cash awardMay 20Filed May 22 · 2d laterSEC filing
Director
Superseded by later filing

Related filings are retained as evidence. This economic transaction is counted once.

This original record remains available as evidence. The later filing replaces it in totals and buying signals.

Superseding SEC filing ↗Original transaction filing ↗
Restricted Stock Unit AwardGrant or awardDerivative units5,409Award · no purchase priceNon-cash awardMay 20Filed May 22 · 2d laterSEC filing
DirectorRestricted Stock Unit AwardOption exercise or conversionDerivative units6,142Exercise / conversion price not reportedNot a separate purchaseMay 21Filed May 22 · 1d laterSEC filing
EVP, CLO, Alkermes, Inc.Ordinary SharesSale10b5-12,034$33.20 / share$67.53KMay 4Filed May 4 · 0d laterSEC filing
EVP R&D, Chief Medical OfficerOrdinary SharesOption exercise or conversion10b5-15,000$19.34 / share$96.7KMay 1Filed May 1 · 0d laterSEC filing
EVP R&D, Chief Medical OfficerOrdinary SharesSale10b5-19,000$33.40 / share$300.56KMay 1Filed May 1 · 0d laterSEC filing
EVP R&D, Chief Medical OfficerEmployee Stock Option (Right to Buy)Option exercise or conversion10b5-1Derivative units5,000$19.34 exercise / conversion priceNot a separate purchaseMay 1Filed May 1 · 0d laterSEC filing
DirectorOrdinary SharesOption exercise or conversion3,751Price not reportedUnavailableApr 11Filed Apr 13 · 2d laterSEC filing
DirectorOrdinary SharesExercise-price or tax withholding901$33.36 / share$30.06KApr 11Filed Apr 13 · 2d laterSEC filing
DirectorRestricted Stock Unit AwardOption exercise or conversionDerivative units3,751Exercise / conversion price not reportedNot a separate purchaseApr 11Filed Apr 13 · 2d laterSEC filing
EVP, CLO, Alkermes, Inc.Ordinary SharesSale10b5-12,034$34.57 / share$70.32KApr 6Filed Apr 6 · 0d laterSEC filing
EVP R&D, Chief Medical OfficerOrdinary SharesOption exercise or conversion10b5-15,000$19.34 / share$96.7KApr 1Filed Apr 1 · 0d laterSEC filing
EVP R&D, Chief Medical OfficerOrdinary SharesSale10b5-19,000$35.51 / share$319.6KApr 1Filed Apr 1 · 0d laterSEC filing
EVP R&D, Chief Medical OfficerEmployee Stock Option (Right to Buy)Option exercise or conversion10b5-1Derivative units5,000$19.34 exercise / conversion priceNot a separate purchaseApr 1Filed Apr 1 · 0d laterSEC filing

Congress transactions 1

All Congress filings
Purchase disclosed

Alkermes plc - Ordinary Shares (ALKS) · Stock

The filing reports a purchase for the member.

Gilbert Cisneros official portraitGilbert CisnerosReporting House member
Reported amount
$15,001 – $50,000Reported range; exact amount not disclosed.
Trade date
July 30, 2026
Filed September 4, 2026 · 36d laterOriginal report
Explore furtherTechnical lab Company financials Test a strategy Compare company

Why this buying score?

No qualifying common-equity purchases

No eligible common-equity purchase is public by this cutoff within 180 transaction-date days. Other instruments, exercises and routine activity do not contribute purchase points.

+0 pts

This score describes qualifying insider purchases at issuer level. Read the methodology

Sources and coverage

Limited filing history · Market-wide discovery does not establish complete company history. View coverage
Source
SEC EDGAR · Form 4
Issuer CIK
0001520262
Latest public acceptance
Oct 2, 2026, 10:22 PM UTC
Score calculated
Oct 8, 2026, 12:07 AM UTC
Parser
form4-parser-1.5
Classifier
form4-classifier-1.1
Scoring methodology
insider-experimental-1.1
Availability
Public filing time, not trade date

Open a transaction's SEC filing for the primary evidence. A code P may describe an open-market or private purchase; classification is not proof of intent.

Insider activity can have many explanations. Signal Strength is not a probability of profit or a recommendation to trade.